Annual FCF
-$33.24 M
-$7.79 M-30.62%
December 31, 2023
Summary
- As of February 8, 2025, CLRB annual free cash flow is -$33.24 million, with the most recent change of -$7.79 million (-30.62%) on December 31, 2023.
- During the last 3 years, CLRB annual FCF has fallen by -$19.25 million (-137.52%).
- CLRB annual FCF is now -1270.76% below its all-time high of -$2.42 million, reached on December 31, 2005.
Performance
CLRB Free Cash Flow Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly FCF
-$9.17 M
+$5.00 M+35.27%
September 30, 2024
Summary
- As of February 8, 2025, CLRB quarterly free cash flow is -$9.17 million, with the most recent change of +$5.00 million (+35.27%) on September 30, 2024.
- Over the past year, CLRB quarterly FCF has increased by +$695.60 thousand (+7.05%).
- CLRB quarterly FCF is now -1469.42% below its all-time high of $669.40 thousand, reached on June 30, 2010.
Performance
CLRB Quarterly FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
TTM FCF
-$46.58 M
-$501.70 K-1.09%
September 30, 2024
Summary
- As of February 8, 2025, CLRB TTM free cash flow is -$46.58 million, with the most recent change of -$501.70 thousand (-1.09%) on September 30, 2024.
- Over the past year, CLRB TTM FCF has dropped by -$13.33 million (-40.11%).
- CLRB TTM FCF is now -15747.23% below its all-time high of -$293.90 thousand, reached on March 31, 2005.
Performance
CLRB TTM FCF Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Free Cash Flow Formula
FCF = Cash From Operations − CAPEX
CLRB Free Cash Flow Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -30.6% | +7.0% | -40.1% |
| 3 y3 years | -137.5% | -42.5% | -112.1% |
| 5 y5 years | -181.1% | -158.4% | -297.5% |
CLRB Free Cash Flow Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3-year | -46.4% | at low | -97.5% | +35.3% | -112.0% | at low |
| 5 y | 5-year | -183.7% | at low | -241.2% | +35.3% | -297.5% | at low |
| alltime | all time | -1270.8% | at low | -1469.4% | +35.3% | <-9999.0% | at low |
Cellectar Biosciences Free Cash Flow History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sep 2024 | - | -$9.17 M(-35.3%) | -$46.58 M(+1.1%) |
| Jun 2024 | - | -$14.16 M(+5.8%) | -$46.07 M(+16.8%) |
| Mar 2024 | - | -$13.38 M(+35.7%) | -$39.44 M(+18.7%) |
| Dec 2023 | -$33.24 M(+30.6%) | -$9.86 M(+13.8%) | -$33.24 M(+7.5%) |
| Sep 2023 | - | -$8.67 M(+15.1%) | -$30.91 M(+5.6%) |
| Jun 2023 | - | -$7.53 M(+4.8%) | -$29.26 M(+6.2%) |
| Mar 2023 | - | -$7.18 M(-4.6%) | -$27.56 M(+8.3%) |
| Dec 2022 | -$25.45 M(+12.1%) | -$7.53 M(+7.3%) | -$25.45 M(+12.8%) |
| Sep 2022 | - | -$7.02 M(+20.4%) | -$22.56 M(+2.7%) |
| Jun 2022 | - | -$5.83 M(+15.0%) | -$21.97 M(-4.6%) |
| Mar 2022 | - | -$5.07 M(+9.2%) | -$23.03 M(+1.4%) |
| Dec 2021 | -$22.71 M(+62.3%) | -$4.64 M(-27.9%) | -$22.71 M(+3.4%) |
| Sep 2021 | - | -$6.43 M(-6.5%) | -$21.96 M(+15.4%) |
| Jun 2021 | - | -$6.88 M(+44.8%) | -$19.02 M(+25.0%) |
| Mar 2021 | - | -$4.75 M(+22.3%) | -$15.23 M(+8.8%) |
| Dec 2020 | -$14.00 M(+19.4%) | -$3.89 M(+11.0%) | -$14.00 M(+9.4%) |
| Sep 2020 | - | -$3.50 M(+13.5%) | -$12.80 M(-0.4%) |
| Jun 2020 | - | -$3.08 M(-12.4%) | -$12.84 M(+3.4%) |
| Mar 2020 | - | -$3.52 M(+31.1%) | -$12.42 M(+6.0%) |
| Dec 2019 | -$11.72 M(-0.9%) | -$2.69 M(-24.3%) | -$11.72 M(-3.6%) |
| Sep 2019 | - | -$3.55 M(+33.2%) | -$12.16 M(+5.0%) |
| Jun 2019 | - | -$2.66 M(-5.6%) | -$11.58 M(+1.0%) |
| Mar 2019 | - | -$2.82 M(-9.8%) | -$11.46 M(-3.1%) |
| Dec 2018 | -$11.83 M(+4.0%) | -$3.13 M(+5.3%) | -$11.83 M(+2.6%) |
| Sep 2018 | - | -$2.97 M(+16.6%) | -$11.53 M(+3.6%) |
| Jun 2018 | - | -$2.55 M(-20.1%) | -$11.13 M(-3.2%) |
| Mar 2018 | - | -$3.19 M(+12.7%) | -$11.50 M(+1.2%) |
| Dec 2017 | -$11.37 M(+36.1%) | -$2.83 M(+10.0%) | -$11.37 M(+3.7%) |
| Sep 2017 | - | -$2.57 M(-11.9%) | -$10.96 M(+3.3%) |
| Jun 2017 | - | -$2.92 M(-4.5%) | -$10.60 M(+10.6%) |
| Mar 2017 | - | -$3.05 M(+26.4%) | -$9.59 M(+14.8%) |
| Dec 2016 | -$8.35 M(+1.0%) | -$2.42 M(+9.1%) | -$8.35 M(+12.1%) |
| Sep 2016 | - | -$2.21 M(+16.2%) | -$7.45 M(+0.6%) |
| Jun 2016 | - | -$1.91 M(+4.8%) | -$7.41 M(-3.8%) |
| Mar 2016 | - | -$1.82 M(+20.2%) | -$7.70 M(-6.9%) |
| Dec 2015 | -$8.27 M(-6.7%) | -$1.51 M(-30.3%) | -$8.27 M(-7.2%) |
| Sep 2015 | - | -$2.17 M(-1.1%) | -$8.91 M(+0.8%) |
| Jun 2015 | - | -$2.20 M(-8.2%) | -$8.84 M(+2.2%) |
| Mar 2015 | - | -$2.39 M(+11.1%) | -$8.65 M(-2.5%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Dec 2014 | -$8.87 M(-4.6%) | -$2.15 M(+2.6%) | -$8.87 M(-5.7%) |
| Sep 2014 | - | -$2.10 M(+4.6%) | -$9.41 M(-5.0%) |
| Jun 2014 | - | -$2.01 M(-23.1%) | -$9.90 M(-0.3%) |
| Mar 2014 | - | -$2.61 M(-3.0%) | -$9.93 M(+6.7%) |
| Dec 2013 | -$9.30 M(+39.2%) | -$2.69 M(+3.7%) | -$9.30 M(+11.2%) |
| Sep 2013 | - | -$2.60 M(+27.6%) | -$8.37 M(+12.0%) |
| Jun 2013 | - | -$2.03 M(+2.6%) | -$7.47 M(+7.5%) |
| Mar 2013 | - | -$1.98 M(+13.0%) | -$6.95 M(+4.0%) |
| Dec 2012 | -$6.68 M(+9.8%) | -$1.75 M(+3.3%) | -$6.68 M(+3.3%) |
| Sep 2012 | - | -$1.70 M(+12.4%) | -$6.47 M(+1.2%) |
| Jun 2012 | - | -$1.51 M(-12.0%) | -$6.39 M(-14.6%) |
| Mar 2012 | - | -$1.72 M(+11.4%) | -$7.48 M(+22.9%) |
| Dec 2011 | -$6.09 M(+79.9%) | -$1.54 M(-4.9%) | -$6.09 M(+30.7%) |
| Sep 2011 | - | -$1.62 M(-37.7%) | -$4.66 M(+27.2%) |
| Jun 2011 | - | -$2.60 M(+701.5%) | -$3.66 M(+834.9%) |
| Mar 2011 | - | -$324.60 K(+187.0%) | -$391.80 K(-88.4%) |
| Dec 2010 | -$3.38 M(-68.2%) | -$113.10 K(-81.9%) | -$3.38 M(-39.1%) |
| Sep 2010 | - | -$623.50 K(-193.1%) | -$5.56 M(-24.0%) |
| Jun 2010 | - | $669.40 K(-120.2%) | -$7.31 M(-30.1%) |
| Mar 2010 | - | -$3.32 M(+44.9%) | -$10.46 M(-1.7%) |
| Dec 2009 | -$10.64 M(-38.8%) | -$2.29 M(-3.7%) | -$10.64 M(-5.8%) |
| Sep 2009 | - | -$2.38 M(-4.3%) | -$11.29 M(-14.6%) |
| Jun 2009 | - | -$2.48 M(-29.0%) | -$13.22 M(-19.9%) |
| Mar 2009 | - | -$3.49 M(+18.6%) | -$16.50 M(-5.0%) |
| Dec 2008 | -$17.38 M(+28.8%) | -$2.94 M(-31.6%) | -$17.38 M(-7.9%) |
| Sep 2008 | - | -$4.30 M(-25.3%) | -$18.86 M(+0.3%) |
| Jun 2008 | - | -$5.76 M(+31.9%) | -$18.81 M(+19.5%) |
| Mar 2008 | - | -$4.37 M(-1.3%) | -$15.74 M(+16.6%) |
| Dec 2007 | -$13.49 M(+108.2%) | -$4.43 M(+4.3%) | -$13.49 M(+19.1%) |
| Sep 2007 | - | -$4.25 M(+57.5%) | -$11.33 M(+20.5%) |
| Jun 2007 | - | -$2.70 M(+26.9%) | -$9.40 M(+19.8%) |
| Mar 2007 | - | -$2.12 M(-6.2%) | -$7.85 M(+21.1%) |
| Dec 2006 | -$6.48 M(+167.2%) | -$2.26 M(-2.5%) | -$6.48 M(+34.0%) |
| Sep 2006 | - | -$2.32 M(+103.1%) | -$4.83 M(+43.3%) |
| Jun 2006 | - | -$1.14 M(+51.7%) | -$3.37 M(+17.0%) |
| Mar 2006 | - | -$753.40 K(+22.0%) | -$2.88 M(+18.9%) |
| Dec 2005 | -$2.42 M | -$617.40 K(-28.3%) | -$2.42 M(+34.2%) |
| Sep 2005 | - | -$860.90 K(+31.9%) | -$1.81 M(+90.9%) |
| Jun 2005 | - | -$652.80 K(+122.1%) | -$946.70 K(+222.1%) |
| Mar 2005 | - | -$293.90 K | -$293.90 K |
FAQ
- What is Cellectar Biosciences annual free cash flow?
- What is the all time high annual FCF for Cellectar Biosciences?
- What is Cellectar Biosciences annual FCF year-on-year change?
- What is Cellectar Biosciences quarterly free cash flow?
- What is the all time high quarterly FCF for Cellectar Biosciences?
- What is Cellectar Biosciences quarterly FCF year-on-year change?
- What is Cellectar Biosciences TTM free cash flow?
- What is the all time high TTM FCF for Cellectar Biosciences?
- What is Cellectar Biosciences TTM FCF year-on-year change?
What is Cellectar Biosciences annual free cash flow?
The current annual FCF of CLRB is -$33.24 M
What is the all time high annual FCF for Cellectar Biosciences?
Cellectar Biosciences all-time high annual free cash flow is -$2.42 M
What is Cellectar Biosciences annual FCF year-on-year change?
Over the past year, CLRB annual free cash flow has changed by -$7.79 M (-30.62%)
What is Cellectar Biosciences quarterly free cash flow?
The current quarterly FCF of CLRB is -$9.17 M
What is the all time high quarterly FCF for Cellectar Biosciences?
Cellectar Biosciences all-time high quarterly free cash flow is $669.40 K
What is Cellectar Biosciences quarterly FCF year-on-year change?
Over the past year, CLRB quarterly free cash flow has changed by +$695.60 K (+7.05%)
What is Cellectar Biosciences TTM free cash flow?
The current TTM FCF of CLRB is -$46.58 M
What is the all time high TTM FCF for Cellectar Biosciences?
Cellectar Biosciences all-time high TTM free cash flow is -$293.90 K
What is Cellectar Biosciences TTM FCF year-on-year change?
Over the past year, CLRB TTM free cash flow has changed by -$13.33 M (-40.11%)